Article citationsMore>>

Latva-Rasku, A., Honka, M., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., et al. (2019) The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study with 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care, 42, 931-937.
https://doi.org/10.2337/dc18-1569

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top